Ginkgo Biloba and Warfarin: A Bleeding Risk the Case Reports Confirm
Ginkgo inhibits platelet activating factor and may amplify warfarin's anticoagulant effect. Case reports of serious bleeding have prompted clinical warnings.
Ginkgo biloba extract is widely taken for cognitive support and circulation. Its effects on blood flow, while modest, are pharmacologically real. For people on anticoagulant therapy, that pharmacological activity is not benign.
Ginkgo’s effect on blood
Ginkgo biloba contains compounds, particularly ginkgolides, that inhibit platelet activating factor (PAF). PAF is a lipid mediator that stimulates platelet aggregation, the clumping of platelets that initiates blood clot formation. By inhibiting PAF, ginkgo reduces platelet aggregation and has a mild anticoagulant effect.
In healthy people without clotting disorders, this effect is considered minor and possibly beneficial for circulation. It is one of the reasons ginkgo has been studied for conditions involving impaired blood flow.
The warfarin overlap
Warfarin is a vitamin K antagonist that prevents clot formation by inhibiting the synthesis of clotting factors. Patients on warfarin require their INR — a measure of how slowly their blood clots — to be maintained within a narrow therapeutic range. Too low, and they are at risk of clots. Too high, and they are at risk of bleeding.
Adding a second antiplatelet agent to a warfarin regimen shifts the balance toward increased bleeding risk. Ginkgo’s PAF-inhibiting activity is independent of warfarin’s mechanism, meaning the two effects can be additive.
Case reports
A 1997 case report documented a fatal subdural haematoma in a patient taking Ginkgo biloba, with no other identified cause. In 2000, a case in Postgraduate Medical Journal described spontaneous bleeding in a patient on warfarin who had added Ginkgo supplementation.
A paper by Matthews in 1998 specifically reviewed the interaction and called for physicians to ask about herbal supplement use in patients on anticoagulant therapy — a practice that was, at the time, not routine.
Randomised controlled data on this specific interaction is limited, because the ethical barriers to conducting such trials are obvious. The clinical concern rests on mechanistic plausibility and a consistent pattern of case reports.
For people on warfarin
The standard advice from clinical pharmacology and haematology is to avoid ginkgo biloba in patients on warfarin, aspirin, clopidogrel, or any other anticoagulant or antiplatelet drug. If a patient is already taking ginkgo and is newly started on warfarin, disclosure to the prescribing physician is essential.
Reference
- Matthews MK Jr. "Association of Ginkgo biloba with intracerebral hemorrhage." Neurology, 1998. PubMed 10861544
